Indicators of antibodies IgM и IgG to SARS-COV-2 in residents of Yakutsk after recovery from COVID-19
https://doi.org/10.25789/YMJ.2021.76.21
Abstract
A study of IgM and IgG antibodies to SARS-COV-2 was carried out in 161 residents of Yakutsk at the age of 20 to 72 years old who had a new coronavirus infection COVID-19 from 3, 6, 9 and 12 months ago. The aim of the work was to evaluate serum immunoglobulins IgM and IgG to SARS-COV-2 in persons who have had COVID-19, depending on the duration and severity of the disease. The intensity of the immune response was assessed using the coefficient of positivity (CP) as the ratio of the optical density of the sample to the critical value of the optical density. According to the results of the study, the seroprevalence in all 4 groups of Covid-19 patients was 100%. Antibodies Ig G and IgM to SARS-CoV-2 in patients with COVID-19 persisted up to 12 months and depended on the postcoid period, age and severity of lung lesions on CT.
About the Authors
S. D. Efremova
Yakutsk Scientific Center for Complex Medical Problems
Russian Federation
Russian Federation
Efremova Svetlana Dmitrievna – junior researcher laboratory of immunology
E. D. Okhlopkova
Yakutsk Scientific Center for Complex Medical Problems
Russian Federation
Russian Federation
Okhlopkova Elena Dmitrievna – Candidate of Biological Sciences, leading researcher, head of the laboratory of Immunology
A. A. Grigorieva
Yakutsk Scientific Center for Complex Medical Problems
Russian Federation
Russian Federation
Grigorieva Anastasia Anatolyevna – researcher, laboratory of biochemistry
L. D. Olesova
Yakutsk Scientific Center for Complex Medical Problems
Russian Federation
Russian Federation
Olesova Lyubov Dygynovna – Candidate of Biological Sciences, leading researcher, head of the Laboratory of Biochemistry
A. N. Romanova
Yakutsk Scientific Center for Complex Medical Problems
Russian Federation
Russian Federation
Romanova Anna Nikolaevna – Doctor of Medical Sciences
References
1. Antibodies IgM and IgG to the SARS-CoV-2 virus in newborns from mothers with COVID-19 / A. A. Semeshkin, V. I. Vechorko, B. V. Silaev [ et al.] // VESTNIK RSMU. - 2020. - №3. -P. 31-34. doi: 10.24075/vrgmu.2020.036
2. Diagnostic characteristics of serological tests for the detection of SARS-CoV-2 cases / O.V. Petrova, D.K. Tverdokhlebova, O.I. Murygina [ et al]. doi:10.51620/0869-2084-2021-66-4-210-212.
3. Long-term symptoms of COVID-19 in residents of Yakutsk / L. D. Olesova, V. A. Makarova, A.I. Yakovleva [ et al.] // Yakutsk Medical Journal. -2021.- No. 3 (75). - P.66-69
4. Ofitserov V.I. Immunoglobulin G Subclasses: Possibilities of Use in Diagnostic Practice / V.I. Ofitserov // Closed Joint Stock Company "Vector-Best" Koltsovo, 2005.-35p.
5. Quantitative assessment of the content of antibodies to SARS-CoV-2 in the plasma of donors / Z. M. Tataeva, A. U. Ataeva E.B. Zhiburt // Hand-book of the head of the CDL, No. 9.-2021 http://www.transfusion.ru/2021/09-15-3.pdf
6. Antibody seroconversion in asymptomatic and symptomatic patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) / Chuanhao Jg, Yali Wg, Min Hu [et al.] //Clin Transl Immunology. -2020. –v.9 (9): e1182. doi:10.1002/cti2.1182
7. Antibody tests for identification of current and past infection with SARS-CoV-2 / Deeks JJ, Dinnes J, Takwoingi Y, [ et al.] //Cochrane Data-base Syst Rev. 2020 Jun 25;6(6):CD013652. doi: 10.1002/14651858.CD013652.
8. Immunologic memory to SARS-CoV-2 in convalescent COVID-19 patients at 1-year postinfection / Hongyan H, Yandi Z 2, Guoxing T, [ et al.] // J Allergy Clin Immunol 2021 Sep 15; S0091-6749(21)01392-0. doi: 10.1016/j.jaci.2021.09.008.
9. Demographic risk factors for COVID-19 infection, severity, ICU admission and death: a meta-analysis of 59 studies / Bart G P, Shahab J, Anique A, [et al.] // BMJ Open 2021 Jan 11;11(1): e044640. doi: 10.1136/bmjopen-2020-044640.
10. Detection of antibodiesagainst SARS-CoV-2 in patients with COVID-19 / Zhe Du, Fengxue Zhu, Fuzheng Guo // J Med Virol.- 2020.- 92(10):1735-1738. doi: 10.1002/jmv.25820
11. Ai Tang Xiao Profile of specific antibodies to SARS-CoV-2: The first report / Ai Tang Xiao, Chun Gao, Sheng Zhang // J Infect. 2020 Jul; 81(1): 147–178. doi:10.1016/j.jinf.2020.03.012
12. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19) / L. Guoo, L. Ren, S. Yang [et al.] // Clin Infect Dis. 2020. Jul 28;71(15): 778-785. doi: 10.1093/cid/ciaa310.
13. Seropositivity rate and diagnostic accuracy of serological tests in 2019-nCoV cases: a pooled analysis of individual studies / C-C Guo, J-Q Mi, H Nie // Eur Rev Med Pharmacol Sci. 2020;24(19):10208-10218. doi: 10.26355/eurrev_202010_23243.
14. Tantuoyir M.M. Serological tests for COVID-19: Potential opportunities /M. M. Tantuoyir, N. Rezaei // Cell Biol Int. 2021 Apr;45(4):740-748. doi: 10.1002/cbin.11516.
Review
For citations:
Efremova S.D., Okhlopkova E.D., Grigorieva A.A., Olesova L.D., Romanova A.N. Indicators of antibodies IgM и IgG to SARS-COV-2 in residents of Yakutsk after recovery from COVID-19. Yakut Medical Journal. 2021;(4):90-93. https://doi.org/10.25789/YMJ.2021.76.21
Views:
15
Email this article 